Xu Guang-Li, Hu Xiao-Fang, Han Yong-Mei, Wei Ai-Wu
Clin Lab. 2018 Jun 1;64(6):1037-1040. doi: 10.7754/Clin.Lab.2018.180130.
To study the clinical effect of low molecular heparin on unexplained recurrent spontaneous abortion (URSA).
A total of 120 URSA patients were collected in our hospital from October 2015 to September 2017. They were divided into two groups: control group (n = 60) and observation group (n = 60). The patients in the control group were administered with progesterone and human chorionic gonadotropin, and the observation group with low molecular heparin. Pregnancy outcomes, incidence of complications in pregnancy and adverse drug reactions were compared in the two groups.
The pregnancy success rate of patients in the observation group (90.00%) is higher than that in the control group (68.33%) (p < 0.05). The incidence of complications in pregnancy in the observation group (90.00%) is lower than those in the control group (68.33%) (p < 0.05). The incidence of adverse drug reactions between the patients in the observation group (20.00%) and those in the control group (23.33%) showed no significant difference (p > 0.05).
Low molecular heparin treatment can improve pregnancy success rate and reduce the incidence of complications in the URSA patients. Low molecular heparin is characterized by safety and reliability and has potential for application in clinic.
研究低分子肝素对不明原因复发性自然流产（URSA）的临床疗效。
收集我院2015年10月至2017年9月期间的120例URSA患者。将其分为两组：对照组（n = 60）和观察组（n = 60）。对照组患者给予黄体酮和人绒毛膜促性腺激素，观察组给予低分子肝素。比较两组的妊娠结局、孕期并发症发生率及药物不良反应。
观察组患者的妊娠成功率（90.00%）高于对照组（68.33%）（p < 0.05）。观察组孕期并发症发生率（90.00%）低于对照组（68.33%）（p < 0.05）。观察组患者（20.00%）与对照组患者（23.33%）的药物不良反应发生率无显著差异（p > 0.05）。
低分子肝素治疗可提高URSA患者的妊娠成功率并降低并发症发生率。低分子肝素具有安全可靠的特点，具有临床应用潜力。
